LENVIMA(R) (lenvatinib) más KEYTRUDA(R) (pembrolizumab) en combinación con Quimioembolización Transarterial (TACE) mejoró significativamente la supervivencia libre de progresión en comparación con TACE solo en pacientes.
The results from the first interim analysis of the Phase 3 LEAP-012 trial are promising, showing a significant improvement in progression-free survival for patients with unresectable, non-metastatic hepatocellular carcinoma when treated with the combination of LENVIMA and KEYTRUDA in addition to TACE. While the overall survival data is still being monitored, the potential for this … Leer más